Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat
about
Chloride channels as drug targets.Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiencyTRPC6 channel translocation into phagosomal membrane augments phagosomal functionCystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesEnhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis.Selection of the biological activity of DNJ neoglycoconjugates through click length variation of the side chain.Applications of proteomic technologies for understanding the premature proteolysis of CFTR.Iminosugars as therapeutic agents: recent advances and promising trends.Pharmacological Correctors of Mutant CFTR Mistrafficking.Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitorsEmergent properties of proteostasis in managing cystic fibrosis.Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanismDiscovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain.The multivalent effect in glycosidase inhibition: probing the influence of valency, peripheral ligand structure, and topology with cyclodextrin-based iminosugar click clusters.Rescue of functional CFTR channels in cystic fibrosis: a dramatic multivalent effect using iminosugar cluster-based correctors.Improvement of chloride transport defect by gonadotropin-releasing hormone (GnRH) in cystic fibrosis epithelial cells.Cystic fibrosis bronchial epithelial cells are lipointoxicated by membrane palmitate accumulation.GBA2-encoded β-glucosidase activity is involved in the inflammatory response to Pseudomonas aeruginosa.Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect.Chemical and pharmacological chaperones as new therapeutic agents.Bcl-2 suppresses sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression in cystic fibrosis airways: role in oxidant-mediated cell deathChemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR traffickingGlycosphingolipids--nature, function, and pharmacological modulation.Update in cystic fibrosis 2009.From pipeline to patient: new developments in cystic fibrosis therapeutics.Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.The multivalent effect in glycosidase inhibition: a new, rapidly emerging topic in glycoscience.Pharmacological treatment of the basic defect in cystic fibrosis.Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator.CFTR and Ca Signaling in Cystic Fibrosis.C terminus of nucleotide binding domain 1 contains critical features for cystic fibrosis transmembrane conductance regulator trafficking and activation.A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype.Abnormal spatial diffusion of Ca2+ in F508del-CFTR airway epithelial cells.Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones.Stimulation of Wild-Type, F508del- and G551D-CFTR Chloride Channels by Non-Toxic Modified pyrrolo[2,3-b]pyrazine Derivatives.Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice.Buserelin alleviates chloride transport defect in human cystic fibrosis nasal epithelial cells.Structure-Activity Studies of N-Butyl-1-deoxynojirimycin (NB-DNJ) Analogues: Discovery of Potent and Selective Aminocyclopentitol Inhibitors of GBA1 and GBA2.Design, synthesis and biological evaluation of bicyclic iminosugar hybrids: conformational constraint as an effective tool for tailoring the selectivity of α-glucosidase inhibitors.
P2860
Q24601830-E7D16AAE-5670-4F38-81DC-D29BFDF3EBE3Q24619820-6AC8AB26-EB6C-4F31-A646-88C5888F9930Q27317729-895C65F3-4258-4399-B4EE-9A1480699ABDQ28073063-AA7E39D3-4997-447F-B288-E76CE09A22E2Q33632575-E96222BA-6E7C-45AF-8EF6-71EBF46161ABQ33879577-971942CC-BCEA-44E8-8F9B-A4D4EC4F6C78Q34076025-82676308-0351-41CA-8483-81F410704F96Q34212463-2F224320-CD53-4CD9-8710-1789753C9A88Q34444239-AFA170F8-7814-47AC-B31E-800541B13F3AQ34532897-9FE98DAE-2DAF-46FA-9F22-3E089C5F9A4DQ34576386-433C7F4D-439C-4D56-869A-4691BF806A63Q34954019-812F8CF0-2308-456D-B580-F7725A7008A6Q34975364-40C03EBC-921B-42BB-9DA3-039F912CA442Q34981135-0B1128A6-90C1-4CB6-BF65-52DF4D064E9BQ34987828-881FC5AF-8737-486B-860E-01EC2CA8C83CQ35106485-8B1F1AC9-52F9-4587-920A-C32EBAFA63C0Q35106583-836917B7-2236-4D2B-A7A4-B9D145B2DA72Q35228672-008975F3-B9C8-4F43-B5B9-BEC6AA08E9DDQ36547077-B20648E8-CDA7-48DA-A8F0-307CAB13D4E2Q36863386-FBE2A2B7-B142-4C13-A8A1-3CDE03807C63Q37175235-2CD93180-A600-430C-959A-B68FE44EA003Q37196094-ED96300C-C267-4DB5-830E-718BE46208FEQ37622816-0F20FABF-21A9-4C40-BBEF-7C51620640AAQ37704053-B9E67936-DE00-4B17-8859-57D3A3AC6282Q38078451-40387E00-987E-4DDC-B53A-80FA6426E8E5Q38097952-CCDBCF1F-4ADE-40BD-829F-2C39DBA2F455Q38113749-297B53E8-5D15-4048-AE03-70862EE1897AQ38210134-5BBA624F-1EE6-452F-BC98-B1780DE7A68EQ38210233-AA9D9AB4-081E-43C9-80A3-C206F5AE923EQ38288541-1E336B33-4558-4552-A312-FA698D2C9794Q38811524-026BBB2B-5D4D-42F9-BB65-57EC58F97EF2Q39708376-75BEBAE4-590A-4B99-A09B-5F79C8777CC7Q39897495-1C9A085E-DE19-43CB-8781-0F05DA86049AQ39923304-9A6D6094-13A2-48FE-8F25-4CA70260842DQ41989850-712739D9-B2D3-4B8D-8B58-9AE4C848007BQ42011265-564F88BE-C5D2-4CFF-8FCE-FA5B9477B049Q46082134-79804DCE-3E0A-4F0E-9DF8-2B77561534B8Q46911058-38635E79-8B42-4982-96BE-639B75175661Q47094962-FED3F337-D2C3-4B30-891C-DE2D5E646280Q51066880-DB33F151-2E10-4A5B-8FC3-C2C550603834
P2860
Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@ast
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@en
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@en-gb
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@nl
type
label
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@ast
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@en
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@en-gb
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@nl
prefLabel
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@ast
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@en
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@en-gb
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@nl
P2093
P2860
P3181
P1433
P1476
Rescue of functional delF508-C ...... lucosidase inhibitor miglustat
@en
P2093
Caroline Norez
Hugo DeJonge
Huub Jorna
Marcel Bijvelds
Martina Wilke
Patricia Melin
P2860
P304
P3181
P356
10.1016/J.FEBSLET.2006.03.010
P407
P577
2006-03-10T00:00:00Z